Literature DB >> 27089554

MRI-based IMRT planning for MR-linac: comparison between CT- and MRI-based plans for pancreatic and prostate cancers.

Phil Prior1, Xinfeng Chen, Maikel Botros, Eric S Paulson, Colleen Lawton, Beth Erickson, X Allen Li.   

Abstract

The treatment planning in radiation therapy (RT) can be arranged to combine benefits of computed tomography (CT) and magnetic resonance imaging (MRI) together to maintain dose calculation accuracy and improved target delineation. Our aim is study the dosimetric impact of uniform relative electron density assignment on IMRT treatment planning with additional consideration given to the effect of a 1.5 T transverse magnetic field (TMF) in MR-Linac. A series of intensity modulated RT (IMRT) plans were generated for two representative tumor sites, pancreas and prostate, using CT and MRI datasets. Representative CT-based IMRT plans were generated to assess the impact of different electron density (ED) assignment on plan quality using CT without the presence of a 1.5 T TMF. The relative ED (rED) values used were taken from the ICRU report 46. Four types of rED assignment in the organs at risk (OARs), the planning target volumes (PTV) and in the non-specified tissue (NST) were considered. Dose was recalculated (no optimization) using a Monaco 5.09.07a research planning system employing Monte Carlo calculations with an option to include TMF. To investigate the dosimetric effect of different rED assignment, the dose-volume parameters (DVPs) obtained from these specific rED plans were compared to those obtained from the original plans based on CT. Overall, we found that uniform rED assignment results in differences in DVPs within 3% for the PTV and 5% for OAR. The presence of 1.5 T TMF on IMRT DVPs resulted in differences that were generally within 3% of the Gold St for both the pancreas and prostate. The combination of uniform rED assignment and TMF produced differences in DVPs that were within 4-5% of the Gold St. Larger differences in DVPs were observed for OARs on T2-based plans. The effects of using different rED assignments and the presence of 1.5 T TMF for pancreas and prostate IMRT plans are generally within 3% and 5% of PTV and OAR Gold St values. There are noticeable dosimetric differences between the CT- and MRI-based IMRT plans caused by a combination of anatomical changes between the two image acquisition times, uniform rED assignment and 1.5 T TMF.

Entities:  

Mesh:

Year:  2016        PMID: 27089554     DOI: 10.1088/0031-9155/61/10/3819

Source DB:  PubMed          Journal:  Phys Med Biol        ISSN: 0031-9155            Impact factor:   3.609


  10 in total

Review 1.  Magnetic resonance image guidance in external beam radiation therapy planning and delivery.

Authors:  Ilamurugu Arivarasan; Chandrasekaran Anuradha; Shanmuga Subramanian; Ayyalusamy Anantharaman; Velayudham Ramasubramanian
Journal:  Jpn J Radiol       Date:  2017-06-13       Impact factor: 2.374

2.  Developing and characterizing MR/CT-visible materials used in QA phantoms for MRgRT systems.

Authors:  Angela Steinmann; R Jason Stafford; Gabriel Sawakuchi; Zhifei Wen; Laurence Court; Clifton D Fuller; David Followill
Journal:  Med Phys       Date:  2017-12-21       Impact factor: 4.071

3.  On the accuracy of bulk synthetic CT for MR-guided online adaptive radiotherapy.

Authors:  Davide Cusumano; Lorenzo Placidi; Stefania Teodoli; Luca Boldrini; Francesca Greco; Silvia Longo; Francesco Cellini; Nicola Dinapoli; Vincenzo Valentini; Marco De Spirito; Luigi Azario
Journal:  Radiol Med       Date:  2019-10-08       Impact factor: 3.469

Review 4.  Magnetic resonance linear accelerator technology and adaptive radiation therapy: An overview for clinicians.

Authors:  William A Hall; Eric Paulson; X Allen Li; Beth Erickson; Christopher Schultz; Alison Tree; Musaddiq Awan; Daniel A Low; Brigid A McDonald; Travis Salzillo; Carri K Glide-Hurst; Amar U Kishan; Clifton D Fuller
Journal:  CA Cancer J Clin       Date:  2021-11-18       Impact factor: 508.702

5.  Optimization of treatment planning workflow and tumor coverage during daily adaptive magnetic resonance image guided radiation therapy (MR-IGRT) of pancreatic cancer.

Authors:  Sven Olberg; Olga Green; Bin Cai; Deshan Yang; Vivian Rodriguez; Hao Zhang; Jin Sung Kim; Parag J Parikh; Sasa Mutic; Justin C Park
Journal:  Radiat Oncol       Date:  2018-03-24       Impact factor: 3.481

6.  Technical Assessment of an Automated Treatment Planning on Dose Escalation of Pancreas Stereotactic Body Radiotherapy.

Authors:  Shuo Wang; Dandan Zheng; Chi Lin; Yu Lei; Vivek Verma; April Smith; Rongtao Ma; Charles A Enke; Sumin Zhou
Journal:  Technol Cancer Res Treat       Date:  2019-01-01

7.  A preferred patient decubitus positioning for magnetic resonance image guided online adaptive radiation therapy of pancreatic cancer.

Authors:  Yazheng Chen; Xinfeng Chen; William Hall; Phil Prior; Ying Zhang; Eric Paulson; Jinyi Lang; Beth Erickson; X Allen Li
Journal:  Phys Imaging Radiat Oncol       Date:  2019-11-20

8.  Planning feasibility of extremely hypofractionated prostate radiotherapy on a 1.5 T magnetic resonance imaging guided linear accelerator.

Authors:  Mariska D den Hartogh; Hans C J de Boer; Eline N de Groot-van Breugel; Jochem R N van der Voort van Zyp; Jochem Hes; Uulke A van der Heide; Floris Pos; Karin Haustermans; Tom Depuydt; Robert Jan Smeenk; Martina Kunze-Busch; Bas W Raaymakers; Linda G W Kerkmeijer
Journal:  Phys Imaging Radiat Oncol       Date:  2019-07-15

9.  Dosimetric Accuracy of MR-Guided Online Adaptive Planning for Nasopharyngeal Carcinoma Radiotherapy on 1.5 T MR-Linac.

Authors:  Shouliang Ding; Hongdong Liu; Yongbao Li; Bin Wang; Rui Li; Xiaoyan Huang
Journal:  Front Oncol       Date:  2022-04-07       Impact factor: 5.738

10.  Mask-Adapted Background Field Removal for Artifact Reduction in Quantitative Susceptibility Mapping of the Prostate.

Authors:  Sina Straub; Julian Emmerich; Heinz-Peter Schlemmer; Klaus H Maier-Hein; Mark E Ladd; Matthias C Röthke; David Bonekamp; Frederik B Laun
Journal:  Tomography       Date:  2017-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.